We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Product
Advertisement

Potentiating CD16-Activated ADCC in CAR-NK Cell Therapy

Potentiating CD16-Activated ADCC in CAR-NK Cell Therapy


NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA) to mediate antibody-dependent cellular cytotoxicity (ADCC). Potentiating therapeutic mAb-mediated CD16 activation of NK cells is an emerging area for cancer immunotherapy.

CAR-NK cells with multi-specific molecules composed of stabilized CD16 and/or other activating receptors (e.g., NKG2D, DNAM-1/CD226, NKp46/NCR1, NKp44/NCR2, and NKp30/NCR3), scFvs for tumor antigens (e.g., CD19, CD22, ROBO1, and PSMA), and cytokine moieties (e.g., IL-15) are being actively studied to augment ADCC. Genetic modifications of CD16 to abolish the sensitivity to ADAM-17 mediated proteolytic cleavage or enhance its affinity for IgG Fc region has shown promising progress. CAR-NK cells expressing CD16A in recombination with the high-affinity Fc receptor, CD64 (FcγRI), show a more stable and enhanced ADCC response, presenting it as a promising advancement in CAR-NK cell immunotherapy.

Sino Biological has developed a panel of quality proteins and antibodies for CD16 and accompanying molecules to support CAR-NK cell therapy research.



About Sino Biological
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.
Interested in seeing more content from Sino Biological?
Discover all their latest news, webinars, products and more by clicking the link below.